ubmslatePT-logo-ubm

PT Mobile Logo

Search form

Topics:

The Interplay of Mood Disorders and Eating Disorders: Page 4 of 4

The Interplay of Mood Disorders and Eating Disorders: Page 4 of 4

Lifetime prevalence of mood disorders in patients with eating disordersTABLE. Lifetime prevalence of mood disorders in patients with eating d...
SIGNIFICANCE FOR THE PRACTICING PSYCHIATRISTSignificance for the Practicing Psychiatrist

 

Pharmacotherapy

Pharmacotherapy remains an important treatment modality for comorbid mood and eating disorders. Given the improvement in mood symptoms with re-nourishment, weight restoration is recommended before evaluation for the need for medication.

SSRIs are effective for the treatment of bulimia nervosa. Fluoxetine was approved by the FDA for the treatment of bulimia nervosa after this agent showed significant efficacy in reducing binge eating and purging behaviors, even in the absence of comorbid depressive disorder.16 Interestingly, fluoxetine was more efficacious for symptoms of bulimia nervosa at a dosage of 60 mg daily than 20 mg daily (the typical dosage for treating depression). However, in a relapse-prevention study in which patients with anorexia nervosa had recently successfully completed full weight restoration through inpatient treatment, fluoxetine was no different than placebo in preventing relapse.17

Bupropion has an FDA “black box” warning for use in patients with bulimia nervosa and anorexia nervosa. It should be generally avoided for treatment of these eating disorders and comorbid depression because it has been linked to a possible increase in seizure risk. In a trial that compared bupropion with placebo for treatment of bulimia nervosa, 4 of 55 women experienced grand mal seizures.18

Other treatment options include lisdexamfetamine, which was approved for the treatment of binge eating disorder after showing efficacy in patients with moderate to severe illness.19 However, clinical trials to date have not compared CBT with lisdexamfetamine in patients with binge eating disorder, and this option may be considered a second- or third-line option after other, more established pharmacotherapies (eg, SSRIs, topiramate) have been ineffective or not tolerated.

Pharmacotherapy for anorexia nervosa and comorbid depression has yielded far less promising results—there is currently no FDA-approved medication for anorexia nervosa. There have been no statistically significant improvements in eating-related or depressive symptoms with antidepressant treatment among individuals with anorexia nervosa.17

In the acute setting, lack of efficacy with antidepressants may be secondary to neurobiological alterations that result from starvation.20 Of mechanistic relevance to this finding may be tryptophan-depletion studies. Patients with depression who were previously in remission with fluoxetine treatment had mood symptom relapse with low tryptophan levels—a nutritional status that may also be caused by malnutrition.21

Pages

Disclosures

Dr Uniacke is an upcoming Chief Resident in the department of psychiatry at the Columbia University Medical Center in New York City. Dr Broft is Assistant Professor of Psychiatry at the Columbia University Medical Center; she is also a psychiatrist in private practice in New York City. The authors report no conflicts of interest concerning the subject matter of this article.

References

1. Reas DL, Ro O, Karterud S, et al. Eating disorders in a large clinical sample of men and women with personality disorders. Int J Eat Disord. 2013;46:801-809.

2. Grilo CM, Sanislow CA, Skodol AE, et al. Do eating disorders co-occur with personality disorders? Comparison groups matter. Int J Eat Disord. 2003;33:155-164.

3. Israel M, Steiger H. Treatment of psychiatric comorbidities. In: Grilo M, Mitchell J, eds. The Treatment of Eating Disorders: A Clinical Handbook. New York: The Guilford Press; 2010:447-457.

4. Pollice C, Kaye W, Greeno C, Weltzin T. Relationship of depression, anxiety, and obsessionality to state of illness in anorexia nervosa. Int J Eat Disord. 1997;21:367-376.

5. Wagner A, Barbarich-Marsteller NC, Frank GK, et al. Personality traits after recovery from eating disorders: do subtypes differ? Int J Eat Disord. 2006; 39:276-284.

6. Sullivan P. Mortality in anorexia nervosa. Am J Psychiatry. 1995;152:1073-1074.

7. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.

8. Franko D, Keel F. Suicidality in eating disorders: occurrence, correlates, and clinical implications. Clin Psychol Rev. 2006;26:769-782.

9. Carano A, DeBerardis D, Campanella D, et al. Alexithymia and suicide ideation in a sample of patients with binge eating disorder. J Psychiatr Pract. 2012;18:5-11.

10. Preti A, Rocchi MB, Sisti D, et al. A comprehensive meta-analysis of the risk of suicide in eating disorders. Acta Psychiatr Scand. 2011;124:6-17.

11. Wilson GT, Grilo CM, Vitousek KM. Psychological treatment of eating disorders. Am Psychol. 2007;62:199-216.

12. Agras WS, Walsh T, Fairburn CG, et al. A multicenter comparison of cognitive-behavioral therapy and interpersonal psychotherapy for bulimia nervosa. Arch Gen Psychiatry. 2000;57:459-466.

13. Grilo CM, Masheb RM, Wilson GT, et al. Cognitive–behavioral therapy, behavioral weight loss, and sequential treatment for obese patients with binge-eating disorder: a randomized controlled trial. J Consult Clin Psychol. 2011;79:675-685.

14. Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68:1324-1332.

15. Champion L, Power MJ. Interpersonal psychotherapy for eating disorders. Clin Psychol Psychother. 2012;19:150-158

16. Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry. 1992;49:139-147.

17. Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA. 2006;295:2605-2612.

18. Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988;49:262-266.

19. McElroy SL, Hudson JI, Mitchell JE, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:235-246.

20. Steinglass J, Mayer L, Attia E. Treatment of restrictive eating and low-weight conditions, including anorexia nervosa and avoidant/restrictive food intake disorder. In: Walsh BT, Sysko R, Glasofer DR, Attia E, eds. Handbook of Assessment and Treatment of Eating Disorders. Arlington, VA: American Psychiatric Association Publishing; 2016:259-277.

21. Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry. 1999;46:212-220.

22. Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007;61:348-358.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.